Pharmacological approaches to enhance mitochondrial biogenesis: focus on PGC-1Α, AMPK, and SIRT1 in cellular health.
Level 5 - mechanism / opinion, no new human data
Systematic review synthesizing preclinical and mechanistic bench studies
PubMed 40019682 · doi:10.1007/s11033-025-10368-8
What was done
Authors conducted a systematic review searching PubMed, Web of Science, and Elsevier for studies published between 2018 and 2023 examining pharmacological agents and targeted drug delivery systems that modulate mitochondrial biogenesis, focusing on PGC-1α, AMPK, and SIRT1.
What was found
The abstract reports no numerical outcomes, effect sizes, or study sample counts. It describes qualitative preclinical findings indicating that agents such as resveratrol, curcumin, metformin, SIRT1 activators, and AMPK agonists can activate mitochondrial biogenesis pathways.
Why it matters
Pharmacological targeting of mitochondrial biogenesis pathways represents an exploratory avenue for metabolic and neurodegenerative disease therapy.
Limits
The abstract provides no quantitative metrics or count of reviewed studies. Evidence is predominantly mechanistic and preclinical, with challenges remaining in drug delivery optimization and clinical translation.
Cited by
- supports Metformin stimulates mitochondrial biogenesis.